Litcius/Paper detail

Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study

Catherine Diefenbach, Brad S. Kahl, Andrew McMillan, Javier Briones, Lalita Banerjee, Raúl Córdoba, Fiona Miall, John M. Burke, Jamie Hirata, Yanwen Jiang, Joseph N. Paulson, Yi Meng Chang, Lisa Musick, Pau Abrisqueta

2021The Lancet Haematology31 citationsDOI

Topics & Concepts

LenalidomideMedicineFollicular lymphomaObinutuzumabInternal medicineRituximabOncologyLymphomaCohortNeutropeniaTolerabilityBrentuximab vedotinGastroenterologyChemotherapyAdverse effectMultiple myelomaCD30Lymphoma Diagnosis and TreatmentOvarian cancer diagnosis and treatmentCutaneous lymphoproliferative disorders research